NCT04370860View on ClinicalTrials.gov

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

CompletedOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

EGFR Exon 19 MutationTumor Progression

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors

lead

National Taiwan University Hospital

OTHER

NCT04370860 - Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants | Biotech Hunter | Biotech Hunter